This STAT+ AI Prognosis newsletter entry is presented as a subscriber-exclusive profile of Insitro CEO Daphne Koller on approaches to speeding up clinical trials with AI. The publicly accessible page contains the headline, author byline, date (Aug. 26, 2026), an image credit to Insitro/STAT, and navigation to related STAT coverage in AI, biotechnology, and health tech.
The item appears in STAT’s AI Prognosis series and signals an interview or feature focused on the intersection of artificial intelligence and drug development, specifically clinical-trials acceleration. The visible content frames the piece as premium analysis available to STAT+ subscribers.
The full article is marked as exclusive to STAT+ subscribers. The page includes a subscriber prompt with subscription options and pricing tiers, login links, and a call to subscribe to unlock the remainder of the story. As presented on the public page, the substantive interview content, specific claims, and any detailed reporting from the conversation with Koller are not available without a STAT+ account.
From the portion of the page accessible without a subscription we can confirm the following factual elements:
The public excerpt does not include quotes, specific methods, program names, trial results, timelines, or any quantitative claims from Koller or Insitro.
The page situates the piece within STAT’s ongoing reporting on artificial intelligence and biotechnology in health care. The site hosts related stories and trackers on generative AI in health, and the AI Prognosis newsletter is positioned as an editorial product that examines whether AI tools in medicine actually work and who benefits or might be harmed.
This context indicates the article likely explores operational or strategic approaches at the intersection of machine learning and clinical development. However, because the substantive interview content is paywalled, the public page does not provide the article’s evidence, examples, or any reported outcomes.
Key substantive details that are not available on the public page and therefore are not reported here include:
Because the source provided is an excerpt behind the STAT+ paywall, those details were not reported and cannot be inferred or summarized here.
The STAT page directs readers to log in or subscribe to STAT+ to read the complete story. Subscription prompts and pricing information are displayed on the page. For readers who require the full interview and its reporting, subscribing to STAT+ or logging into an existing STAT+ account is the route indicated by the publisher to access the remainder of the article.
If you would like, I can outline typical topics and evidence one would expect in an in-depth interview about using AI to accelerate clinical trials (for example: synthetic control arms, predictive biomarkers, patient selection models, adaptive trial designs), clearly labeled as general context rather than sourced content. The source article’s substantive reporting and any attributed statements to Insitro or Daphne Koller were not available on the public page and are therefore not included above.